EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Intratumoral CD103 + CD8 + T cells predict response to neoadjuvant chemoimmunotherapy in advanced head and neck squamous cell carcinoma

Siqi Ren, Tianjun Lan, Fan Wu, Suling Chen, Xue Jiang, Chuying Huo, Zitian Li, Shule Xie, Donghui Wu, Ruixin Wang, Yanyan Li, Lin Qiu and 8 more

Cancer Communications · 2023-10 · 43 (10) · 1143-1163

DOI: 10.1002/cac2.12480 ↗

At a glance

Journal article in Cancer Communications, published online on 2023-09-01. Written by Siqi Ren and 19 co-authors. Institution: Department of Oral and Maxillofacial Surgery, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangdong, P. R. China. Major MEDLINE topics: CD8-Positive T-Lymphocytes, Head and Neck Neoplasms. Cited 48 times so far (Crossref); 52 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: China Postdoctoral Science Foundation, National Natural Science Foundation of China, Guangzhou Municipal Science and Technology Project.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Immune cell heterogenicity is known to determine the therapeutic response to cancer progression. Neoadjuvant chemoimmunotherapy (NACI) has shown clinical benefits in some patients with advanced head and neck squamous cell carcinoma (HNSCC), but the underlying mechanism behind this clinical response is unknown. The efficacy of NACI needs to be potentiated by identifying accurate biomarkers to predict clinical responses. Here, we attempted to identify molecules predicting NACI response in advanced HNSCC.

Methods

We performed combined single‐cell RNA sequencing (scRNA‐seq) and multiplex immunofluorescence (mIHC) staining with tumor samples derived from NACI‐treated HNSCC patients to identify a new tumor‐infiltrating cell (TIL) subtype, CD103 + CD8 + TILs, associated with clinical response, while both in vitro and in vivo assays were carried out to determine its antitumor efficiency. The regulatory mechanism of the CD103 + CD8 + TILs population was examined by performing cell‐cell interaction analysis of the scRNA‐seq data and spatial analysis of the mIHC images.

Results

We established intratumoral CD103 + CD8 + TILs density as a determinant of NACI efficacy in cancers. Our scRNA‐seq results indicated that the population of CD103 + CD8 + TILs was dramatically increased in the responders of NACI‐treated HNSCC patients, while mIHC analysis confirmed the correlation between intratumoral CD103 + CD8 + TILs density and NACI efficacy in HNSCC patients. Further receiver operating characteristic curve analysis defined this TIL subset as a potent marker to predict patient response to NACI. Functional assays showed that CD103 + CD8 + TILs were tumor‐reactive T cells, while programmed cell death protein‐1 (PD‐1) blockade enhanced CD103 + CD8 + TILs cytotoxicity against tumor growth in vivo. Mechanistically, targeting the triggering receptor expressed on myeloid cells 2‐positive (TREM2 + ) macrophages might enhance the population of CD103 + CD8 + TILs and facilitate antitumor immunity during NACI treatment.

Conclusions

Our study highlights the impact of intratumoral CD103 + CD8 + TILs density on NACI efficacy in different cancers, while the efforts to elevate its population warrant further clinical investigation.

Subjects

MeSH terms (MEDLINE)

CD8-Positive T-LymphocytesHead and Neck NeoplasmsHumansSquamous Cell Carcinoma of Head and NeckNeoadjuvant Therapy

Author keywords

CD103CD8head and neck squamous cell carcinomaneoadjuvant chemoimmunotherapypredictive markertumor-infiltrating lymphocyte

Authors and institutions

  • Department of Oral and Maxillofacial Surgery, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangdong, P. R. China.
  • Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen Universi…
  • Department of Gynecological Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangdong, P. R. China.
  • School of Stomatology, Jilin University, Jilin, P. R. China.
  • Stomatology Hospital of Haizhu district, Guangdong, P. R. China.

ORCID profiles: Jinsong Li

Funding

  • China Postdoctoral Science Foundation
  • National Natural Science Foundation of China
  • Guangzhou Municipal Science and Technology Project

Cite

APA

Ren, S., Lan, T., Wu, F., Chen, S., Jiang, X., Huo, C., Li, Z., Xie, S., Wu, D., Wang, R., Li, Y., Qiu, L., Huang, G., Li, S., Wang, X., Cen, M., Cai, T., Lin, Z., Li, J., & Li, B. (2023). Intratumoral CD103 + CD8 + T cells predict response to neoadjuvant chemoimmunotherapy in advanced head and neck squamous cell carcinoma. Cancer Communications, 43(10), 1143-1163. https://doi.org/10.1002/cac2.12480

Vancouver

Ren S, Lan T, Wu F, Chen S, Jiang X, Huo C, et al. Intratumoral CD103 + CD8 + T cells predict response to neoadjuvant chemoimmunotherapy in advanced head and neck squamous cell carcinoma. Cancer Communications. 2023;43(10):1143-1163. doi:10.1002/cac2.12480

BibTeX
@article{Ren2023,
  author = {Ren, Siqi and Lan, Tianjun and Wu, Fan and Chen, Suling and Jiang, Xue and Huo, Chuying and Li, Zitian and Xie, Shule and Wu, Donghui and Wang, Ruixin and Li, Yanyan and Qiu, Lin and Huang, Guoxin and Li, Shurui and Wang, Xiaojuan and Cen, Meifeng and Cai, Tingting and Lin, Zhaoyu and Li, Jinsong and Li, Bowen},
  title = {Intratumoral CD103 + CD8 + T cells predict response to neoadjuvant chemoimmunotherapy in advanced head and neck squamous cell carcinoma},
  journal = {Cancer Communications},
  year = {2023},
  volume = {43},
  number = {10},
  pages = {1143--1163},
  doi = {10.1002/cac2.12480}
}
Start for free →